John Oyler, BeiGene CEO (Endpoints News, PharmCube)
November 24, 2021 06:43 AM EST
Financing
China

BeiGene gets the ball rolling on its 3rd IPO — and this one is ex­pect­ed to fetch $3B

Amber Tong

BeiGene was among the first Chi­na-based biotech com­pa­nies to list on Nas­daq and made his­to­ry by rais­ing $903 mil­lion in its sec­ondary list­ing in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

IN8bio’s Phase 1 AML da­ta; Lay­offs at Q32 Bio and Third Har­mon­ic

In­ven­ti­va cuts pipeline, lays off near­ly en­tire re­search team in bid to get to Phase 3 MASH read­out

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times